SU5416 (Semaxanib): Selective VEGFR2 Inhibitor for Angiogenesis and Immune Modulation

Executive Summary: SU5416 (Semaxanib) is a highly selective small-molecule inhibitor of the vascular endothelial growth factor receptor 2 (VEGFR2), targeting the Flk-1/KDR receptor tyrosine kinase with nanomolar potency (APExBIO). It blocks VEGF-induced phosphorylation and downstream signaling, suppressing angiogenesis and tumor vascularization (Zhang et al., 2024). SU5416 also acts as an agonist for the aryl hydrocarbon receptor (AHR), modulating immune responses via IDO induction. Its solubility profile and dosing parameters are well-characterized for in vitro and in vivo work. Extensive validation in xenograft and pulmonary hypertension models underscores its utility in translational research.

Biological Rationale

Angiogenesis is essential for tumor growth and progression, mediated primarily by VEGF signaling through VEGFR2 (Flk-1/KDR) on endothelial cells. Pathological angiogenesis is implicated in cancer, pulmonary arterial hypertension (PAH), and chronic inflammation (Zhang et al., 2024). Inhibition of VEGFR2 activity disrupts endothelial proliferation and neovascularization, providing a mechanistic basis for anti-cancer and anti-angiogenic strategies. Additionally, immune modulation via the aryl hydrocarbon receptor (AHR) pathway, leading to upregulation of indoleamine 2,3-dioxygenase (IDO), links angiogenesis regulation to immune tolerance and autoimmunity control (see applied protocols). SU5416 (SKU: A3847) is positioned as a dual-action molecule for these intersecting biological axes.

Mechanism of Action of SU5416 (Semaxanib) VEGFR2 inhibitor

SU5416 competitively binds to the ATP-binding site of VEGFR2, inhibiting its kinase activity and thus preventing VEGF-induced receptor phosphorylation (APExBIO). This blockade halts downstream signaling cascades (including MAPK/ERK and PI3K/AKT) that drive endothelial cell proliferation and migration. In HUVEC cells, SU5416 demonstrates an IC₅₀ of 0.04±0.02 μM for VEGF-driven mitogenesis. In vivo, it reduces tumor vascular density and growth at daily intraperitoneal doses of 1–25 mg/kg (4°C storage, DMSO-soluble; insoluble in water/ethanol). Beyond VEGFR2, SU5416 is a functional agonist of AHR, triggering IDO expression and stimulating regulatory T cell (Treg) differentiation, contributing to immune tolerance (strategic horizon article).

Evidence & Benchmarks

• SU5416 inhibits VEGF-induced phosphorylation of VEGFR2 (Flk-1/KDR) in endothelial cells at nanomolar concentrations, with IC₅₀ = 0.04±0.02 μM in HUVEC assays (APExBIO).
• In mouse xenograft models, daily intraperitoneal administration of SU5416 at 1–25 mg/kg significantly suppresses tumor growth without observed mortality at higher tested doses (APExBIO).
• SU5416 combined with hypoxia in rat models is widely used to induce pulmonary arterial hypertension by selective endothelial injury, mirroring human PAH pathobiology (Zhang et al., 2024).
• SU5416 acts as an AHR agonist, leading to upregulation of IDO and increased regulatory T cell differentiation, contributing to immune tolerance in transplant and autoimmune models (protocol guide).
• Solubility in DMSO is ≥11.9 mg/mL; insoluble in ethanol and water. Working solutions are stable for months at −20°C when protected from light (APExBIO).

Applications, Limits & Misconceptions

SU5416 is primarily used in:

• Cancer research for inhibition of VEGF-dependent angiogenesis and tumor growth (benchmarking article)
• Preclinical models of pulmonary arterial hypertension (PAH) for selective endothelial injury and disease induction (Zhang et al., 2024)
• Studies of immune modulation, particularly AHR-IDO-Treg axis in autoimmunity and transplantation (protocols)

This article extends prior discussions, such as the mechanistic overview, by focusing on atomic in vitro/in vivo performance parameters and translational benchmarks.

Common Pitfalls or Misconceptions

• SU5416 is not effective against VEGFR1 or VEGFR3 at concentrations selective for VEGFR2; off-target effects require higher doses.
• Its use as a PAH inducer in rodents does not model chronic human PAH etiology; it primarily induces endothelial injury when combined with hypoxia (Zhang et al., 2024).
• It is insoluble in water and ethanol; failed dissolution in these solvents compromises experimental validity.
• SU5416 is not cytotoxic at standard in vitro concentrations (≤100 μM), but higher concentrations or prolonged exposure may affect off-target kinases.
• Its immune modulatory effects are dependent on intact AHR signaling; results may vary in AHR-deficient models.

Workflow Integration & Parameters

For in vitro studies, stock solutions are prepared in DMSO (≥11.9 mg/mL), optionally warmed to 37°C or sonicated. Working concentrations for cell-based assays range from 0.01 to 100 μM, with reproducible inhibition of VEGFR2 signaling in HUVEC and other endothelial cells. For in vivo studies, daily intraperitoneal dosing (1–25 mg/kg) is standard in mouse and rat models. Solutions should be protected from light and stored at −20°C. APExBIO supplies SU5416 (A3847) with validated purity and stability profiles (SU5416 (Semaxanib) VEGFR2 inhibitor). For troubleshooting and advanced applications, see this Q&A-driven guide, which complements the present atomic review with practical assay optimizations.

Conclusion & Outlook

SU5416 (Semaxanib) is a benchmark selective VEGFR2 inhibitor with dual utility in angiogenesis research and immune modulation. Its validated potency, specificity, and integration into both cancer and vascular disease models make it indispensable for translational studies. The compound’s robust performance in PAH and tumor xenograft models, as well as its utility in dissecting AHR-mediated immunoregulatory pathways, position it as a core tool for mechanistic and applied research. Ongoing work should focus on further defining its off-target spectrum and optimizing dosing strategies for emerging disease models. For full technical specifications, refer to the APExBIO product page.